erlotinib hydrochloride has been researched along with lg 100268 in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (lg 100268) | Trials (lg 100268) | Recent Studies (post-2010) (lg 100268) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 108 | 0 | 28 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | lg 100268 (IC50) |
|---|---|---|---|
| Retinoic acid receptor RXR-alpha | Homo sapiens (human) | 0.008 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Black, CC; Dmitrovsky, E; Gribble, GW; Honda, T; Lamph, WW; Liby, K; Liu, X; Risingsong, R; Royce, DB; Sporn, MB; Sporn, TA; Williams, CR; Yore, MM | 1 |
1 other study(ies) available for erlotinib hydrochloride and lg 100268
| Article | Year |
|---|---|
The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis.
Topics: Animals; Anticarcinogenic Agents; Cell Line, Tumor; Erlotinib Hydrochloride; Female; Lung; Lung Neoplasms; Mice; Nicotinic Acids; Oleanolic Acid; Protein Kinase Inhibitors; Quinazolines; Tetrahydronaphthalenes | 2008 |